Research

News alert: Link11’s research shows DDoS attacks are more targeted — and doubled — year-over-year – Go Health Pro

by
News alert: Link11’s research shows DDoS attacks are more targeted — and doubled — year-over-year – Go Health Pro

Frankfurt, Germany, Mar. 17, 2025, CyberNewswire — Cyberattacks are no longer an abstract threat – they dominate risk planning for companies worldwide. The latest Link11 European Cyber Report shows an alarming trend: the number of DDoS attacks has more than doubled, and they are shorter, more targeted, and more technically sophisticated. Organizations that do not … Read more

Zacks Small Cap Research – CBAT: Reasons for optimism are on the horizon as the company discusses new expansion plans. – Go Health Pro

by

By Brian Lantier, CFA NASDAQ:CBAT READ THE FULL CBAT RESEARCH REPORT CBAK Energy Reports Full Year 2024 Results On Monday, March 17th, CBAK Energy Technology (NASDAQ:CBAT) released its full-year results which saw many of the trends of 2024 continue into the fourth quarter including profound weakness in the raw material business. While we will have … Read more

Zacks Small Cap Research – SDOT: Sadot Group Reports 2024 Financial Results Which Showed the First Full Year Positive Net Income in the Company’s History – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:SDOT READ THE FULL SDOT RESEARCH REPORT 4th Quarter and Full Year 2024 Financial Results On March 11, 2025, Sadot Group (NASDAQ:SDOT) reported 4th quarter and full year 2024 results which showed continued strength in the commodity trading business. In the latest filings, the restaurant operations have been reported as discontinued … Read more

Zacks Small Cap Research – MGRM: Monogram Technologies Reports 4th Quarter and Full Year 2024 Results – Go Health Pro

by
Zacks Small Cap Research – MGRM: Monogram Technologies Reports 4th Quarter and Full Year 2024 Results – Go Health Pro

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT 4th Quarter and Full Year 2024 Financial Results Monogram (NASDAQ:MGRM) reported 4th quarter and full year 2024 financial results on March 12th which were largely in line with our expectations. Research and development expenses for 2024 were $8.8 million compared to $10.6 million in … Read more

Zacks Small Cap Research – RERE: 4Q24 Earnings Review: EPS as Expected; Investing for Growth to Keep Pace with Accelerating Demand – Go Health Pro

by

By Michael Kim NYSE:RERE READ THE FULL RERE RESEARCH REPORT Pre-market open on 3/11/25, ATRenew (NYSE:RERE) reported 4Q24 earnings results. On a GAAP basis, RERE reported net income of $10.6 million for 4Q24, or $0.04 per ADS. That said, excluding non-cash share-based compensation and intangible assets amortization expenses, adjusted EPS came in at $0.07, or … Read more

x